

11 April 2023

Deltex Medical Group plc
("Deltex Medical", the "Company" or the "Group")

Issue of equity to satisfy certain outstanding equity-settled non-executive directors' fees

The Board of Deltex Medical (AIM: DEMG), the global leader in oesophageal doppler monitoring, announces the issue of 9,993,805 new ordinary shares of 1p each in the capital of the Company ("Ordinary Shares"), at an issue price of 1.1 pence per new Ordinary Share (the "Issue Price"). The Issue Price represents the Company's closing mid-market price on 6 April 2023.

The new Ordinary Shares are being issued in order to satisfy certain deferred non-executive directors' fees for the year ended 31 December 2021 ("Fee Shares"). In previous years, the Company has settled the deferred non-executive directors' fees of a calendar year in July of the following year. This was last done on 16 July 2021 in respect of the fees ended 31 December 2020. The fees for the year ended 31 December 2021 were expected to be settled on or around July 2022. However, the Company was in and has continued to be in a closed period since that time. Following the publication of the results for the year ended 31 December 2022, the Company is now in a position to settle such outstanding non-executive directors' fees.

Further details of the new Ordinary Shares to be issued to each of the Deltex Medical directors are set out in the table below.

Director	Current Ordinary Shares held	Fee Shares issued	<i>Resultant holding post Fee Shares</i>	
			Ordinary Shares Held	As a percentage of the enlarged share capital
Nigel Keen	99,852,821	3,448,351	103,301,172	14.57%
Julian Cazalet	27,153,971	2,181,818	29,335,789	4.14%
Mark Wippell	11,037,875	2,181,818	13,219,693	1.86%
Chris Jones	4,297,291	2,181,818	6,479,109	0.91%

Application for admission to trading and total voting rights

Application has been made for 9,993,805 new Ordinary Shares to be admitted to trading on AIM, which is expected to take effect on or around 17 April 2023 ("Admission").

Following Admission, the Company's issued share capital will comprise 709,057,601 Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

For further information, please contact:

Deltex Medical Group plc
Nigel Keen, Chairman
Andy Mears, Chief Executive
Natalie Wettler, Group Finance Director

01243 774 837
investorinfo@Deltexmedical.com

Nominated Adviser and Broker
Allenby Capital Limited

020 3328 5656

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:

1.	Details of the person discharging managerial responsibilities / person closely associated																		
a)	Name	PDMRs: <table border="1"> <tr> <td>Nigel Keen</td> <td>Non-Executive Director - Chairman</td> </tr> <tr> <td>Julian Cazalet</td> <td>Non-Executive Director</td> </tr> <tr> <td>Mark Wippell</td> <td>Non-Executive Director</td> </tr> <tr> <td>Chris Jones</td> <td>Non-Executive Director</td> </tr> </table>			Nigel Keen	Non-Executive Director - Chairman	Julian Cazalet	Non-Executive Director	Mark Wippell	Non-Executive Director	Chris Jones	Non-Executive Director							
Nigel Keen	Non-Executive Director - Chairman																		
Julian Cazalet	Non-Executive Director																		
Mark Wippell	Non-Executive Director																		
Chris Jones	Non-Executive Director																		
2.	Reason for the Notification																		
a)	Position/status	See 1a) above																	
b)	Initial notification/Amendment	Initial Notification																	
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor																		
a)	Name	Deltex Medical Group Plc																	
b)	LEI	213800XN34P6L8J6M39																	
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted																		
a)	Description of the Financial instrument, type of instrument	Ordinary shares of 0.1p each in Deltex Medical Group Plc																	
	Identification code	ISIN: GB0059337583																	
b)	Nature of the transaction	Fee shares																	
c)	Price(s) and volume(s)	<table border="1"> <tr> <th>Name</th> <th>Price(s)</th> <th>Volume(s)</th> </tr> <tr> <td>Nigel Keen</td> <td>1.1p</td> <td>3,448,351</td> </tr> <tr> <td>Julian Cazalet</td> <td>1.1p</td> <td>2,181,818</td> </tr> <tr> <td>Mark Wippell</td> <td>1.1p</td> <td>2,181,818</td> </tr> <tr> <td>Chris Jones</td> <td>1.1p</td> <td>2,181,818</td> </tr> </table>			Name	Price(s)	Volume(s)	Nigel Keen	1.1p	3,448,351	Julian Cazalet	1.1p	2,181,818	Mark Wippell	1.1p	2,181,818	Chris Jones	1.1p	2,181,818
Name	Price(s)	Volume(s)																	
Nigel Keen	1.1p	3,448,351																	
Julian Cazalet	1.1p	2,181,818																	
Mark Wippell	1.1p	2,181,818																	
Chris Jones	1.1p	2,181,818																	
d)	Aggregated information:																		
	- Aggregated volume	9,993,805																	
	- Price	1.1p																	
e)	Date of the transaction	11 April 2023																	
f)	Place of the transaction	Outside a trading venue																	

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

IOESFAFMFEDSED